(C) Reuters. FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar
(Reuters) -Eli Lilly and Co said on Thursday it had received a subpoena from the U.S. Department of Justice related to its New Jersey plant that makes its COVID-19 treatment, bamlanivimab.
The subpoena requested certain documents relating to its site in Branchburg, New Jersey, and the company is cooperating with the investigation, Eli Lilly (NYSE:LLY) said. It did not specify what documents the subpoena requested.
Reuters reported earlier this month that the company’s employees have accused a factory executive of altering documents required by government regulators to downplay serious quality control problems at the Branchburg site.
The U.S. Food and Drug Administration’s inspectors visited the Branchburg plant in November 2019 and found data on various manufacturing processes had been deleted and not appropriately audited, Reuters reported last year.
The drugmaker said on Thursday it had previously engaged external counsel to conduct an independent investigation of certain allegations relating to the Branchburg plant, without specifying the allegations.
Eli Lilly is also under pressure due to quality control, production and regulatory issues at its Indianapolis plant, which bottles bamlanivimab, among other drugs.
Last year, Eli Lilly hired an independent consultant to review the New Jersey plant after receiving an Official Action Indicated notice from the U.S. health regulator.
Eli Lilly receives DoJ subpoena over COVID-19 drug manufacturing plant
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.